Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TIMP3 | P35625 | 1/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 9/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 8/20 | 0.48 |
| ▸ | CA12 | O43570 | 7/20 | 0.48 |
| ▸ | CA9 | Q16790 | 7/20 | 0.48 |
| ▸ | CA4 | P22748 | 5/20 | 0.48 |
| ▸ | CA7 | P43166 | 5/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13724331 | 0.91 | GHSR (0.51) | TIMP3PRMT1KDM4EL3MBTL1CA2 | |
| SCHEMBL13723881 | 0.82 | MAPT (0.62) | KDM4ECA2MAPTSMN1; SMN2CA1 | |
| SCHEMBL11596260 | 0.80 | GHSR (0.63) | MAPTGHSRKMT2A | |
| SCHEMBL14429911 | 0.80 | GHSR (0.70) | GHSR | |
| SCHEMBL13714615 | 0.80 | DHODH (0.57) | TIMP3CA2CA1CA12CA9 | |
| SCHEMBL10939812 | 0.80 | CNR1 (0.70) | KDM4ESMN1; SMN2CNR1 | |
| SCHEMBL14155782 | 0.80 | PRMT1 (0.77) | TIMP3PRMT1KDM4ECA2MAPT | |
| SCHEMBL6690096 | 0.80 | MAOA (0.53) | CA2MAPTSMN1; SMN2CA1CA12 | |
| SCHEMBL13714744 | 0.79 | GHSR (0.58) | GHSR | |
| SCHEMBL11592875 | 0.79 | DHODH (0.56) | TIMP3CA2CA1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034888-B2 | Substituted 2-imidazolidones and analogs | UNIVERSITE LAVAL (CA) | 2015-05-19 | — | — | US | disclosed |
| EP-2536693-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | Université Laval (CA) | 2012-12-26 | — | — | EP | disclosed |
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | UNIVERSITE LAVAL (CA) | 2012-12-06 | — | — | US | disclosed |
| WO-2012142698-A1 | ALKYLUREA DERIVATIVES ACTIVE AGAINST CANCER CELLS | UNIVERSITE LAVAL (CA) | 2012-10-26 | — | — | WO | disclosed |
| WO-2011100840-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | UNIVERSITé LAVAL (CA) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | CCNY, RPS4Y1, TPX2 | TIMP3 4044/4885PRMT1 38/4885KDM4E 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.